CA2865332C - Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof - Google Patents

Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof Download PDF

Info

Publication number
CA2865332C
CA2865332C CA2865332A CA2865332A CA2865332C CA 2865332 C CA2865332 C CA 2865332C CA 2865332 A CA2865332 A CA 2865332A CA 2865332 A CA2865332 A CA 2865332A CA 2865332 C CA2865332 C CA 2865332C
Authority
CA
Canada
Prior art keywords
alkyl
phenyl
compound
cooh
conh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2865332A
Other languages
English (en)
French (fr)
Other versions
CA2865332A1 (en
Inventor
Wendelin Frick
Heiner Glombik
Stefan Theis
Hubert Heuer
Hans-Ludwig Schaefer
Werner Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CA2865332A1 publication Critical patent/CA2865332A1/en
Application granted granted Critical
Publication of CA2865332C publication Critical patent/CA2865332C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2865332A 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof Active CA2865332C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006053635.5 2006-11-14
DE102006053635A DE102006053635B4 (de) 2006-11-14 2006-11-14 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CA2669230A CA2669230C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2669230A Division CA2669230C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof

Publications (2)

Publication Number Publication Date
CA2865332A1 CA2865332A1 (en) 2008-05-22
CA2865332C true CA2865332C (en) 2016-03-29

Family

ID=39092812

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2865332A Active CA2865332C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
CA2669230A Active CA2669230C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2669230A Active CA2669230C (en) 2006-11-14 2007-10-30 Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof

Country Status (37)

Country Link
US (1) US7956085B2 (OSRAM)
EP (1) EP2084172B1 (OSRAM)
JP (1) JP5301453B2 (OSRAM)
KR (1) KR101489168B1 (OSRAM)
CN (1) CN101535326B (OSRAM)
AR (2) AR063786A1 (OSRAM)
AT (1) ATE492554T1 (OSRAM)
AU (1) AU2007321496B2 (OSRAM)
BR (1) BRPI0718813B8 (OSRAM)
CA (2) CA2865332C (OSRAM)
CL (1) CL2007003262A1 (OSRAM)
CO (1) CO6190534A2 (OSRAM)
CR (1) CR10733A (OSRAM)
CY (1) CY1111166T1 (OSRAM)
DE (2) DE102006053635B4 (OSRAM)
DK (1) DK2084172T3 (OSRAM)
EC (1) ECSP099327A (OSRAM)
ES (1) ES2358371T3 (OSRAM)
GT (1) GT200900125A (OSRAM)
HR (1) HRP20110197T1 (OSRAM)
IL (1) IL198718A (OSRAM)
MA (1) MA30883B1 (OSRAM)
MX (1) MX2009003958A (OSRAM)
MY (1) MY148429A (OSRAM)
NI (1) NI200900076A (OSRAM)
NO (2) NO342236B1 (OSRAM)
NZ (1) NZ576762A (OSRAM)
PE (1) PE20081493A1 (OSRAM)
PL (1) PL2084172T3 (OSRAM)
PT (1) PT2084172E (OSRAM)
RU (1) RU2456282C2 (OSRAM)
SI (1) SI2084172T1 (OSRAM)
SV (1) SV2009003216A (OSRAM)
TN (1) TN2009000180A1 (OSRAM)
TW (1) TWI414530B (OSRAM)
UY (1) UY30709A1 (OSRAM)
WO (1) WO2008058628A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2282991T3 (en) * 2008-05-02 2018-05-07 Sanofi Aventis Deutschland METHOD OF PREPARING 1,4-BENZOTHIEPINE-1,1-DIOXIDE DERIVATIVES
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
JP5889321B2 (ja) 2010-11-04 2016-03-22 アルビレオ アクチエボラグ 肝疾患の処置用のｉｂａｔ阻害剤
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX363161B (es) 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
WO2013063512A1 (en) * 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019245448A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
PT3923943T (pt) 2019-02-12 2024-10-23 Mirum Pharmaceuticals Inc Resposta dependente da dose e do genótipo a um asbti em doentes com deficiência na bomba de exportação de sais biliares
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
MX2022006731A (es) 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Ａｓｂｔ阻害剤の皮下投与
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases
US20240382507A1 (en) * 2023-05-19 2024-11-21 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising 2,3,4,5- tetrahydrobenzothiepin- 1,1-dioxide derivatives and the use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
RU2297222C2 (ru) * 2001-08-22 2007-04-20 Санофи-Авентис Дойчланд Гмбх Комбинированные препараты из производных 1,4-бензотиепин-1,1-диоксида с другими биологически активными веществами и их применение
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
BR0213501A (pt) 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
DE102005033099A1 (de) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung

Also Published As

Publication number Publication date
NO342236B1 (no) 2018-04-23
BRPI0718813B8 (pt) 2021-05-25
DE102006053635A1 (de) 2008-05-15
SI2084172T1 (sl) 2011-03-31
MY148429A (en) 2013-04-30
NI200900076A (es) 2010-01-29
NZ576762A (en) 2010-11-26
RU2009122470A (ru) 2010-12-20
ECSP099327A (es) 2009-06-30
CY1111166T1 (el) 2015-06-11
IL198718A0 (en) 2010-02-17
DK2084172T3 (da) 2011-04-04
CN101535326A (zh) 2009-09-16
KR101489168B1 (ko) 2015-02-03
ATE492554T1 (de) 2011-01-15
TW200837072A (en) 2008-09-16
US20100035961A1 (en) 2010-02-11
NO20180497A1 (no) 2009-07-09
PE20081493A1 (es) 2008-11-24
CO6190534A2 (es) 2010-08-19
IL198718A (en) 2012-12-31
JP5301453B2 (ja) 2013-09-25
ES2358371T3 (es) 2011-05-10
CL2007003262A1 (es) 2008-05-30
GT200900125A (es) 2011-06-23
AR109033A2 (es) 2018-10-24
JP2010509379A (ja) 2010-03-25
TWI414530B (zh) 2013-11-11
CR10733A (es) 2009-05-25
WO2008058628A1 (de) 2008-05-22
CA2669230C (en) 2015-01-13
KR20090082396A (ko) 2009-07-30
PL2084172T3 (pl) 2011-06-30
NO20091893L (no) 2009-07-09
AR063786A1 (es) 2009-02-18
EP2084172B1 (de) 2010-12-22
HRP20110197T1 (hr) 2011-04-30
DE502007006055D1 (de) 2011-02-03
CA2865332A1 (en) 2008-05-22
CA2669230A1 (en) 2008-05-22
SV2009003216A (es) 2010-05-26
BRPI0718813A2 (pt) 2013-12-03
PT2084172E (pt) 2011-02-10
HK1137762A1 (en) 2010-08-06
RU2456282C2 (ru) 2012-07-20
AU2007321496B2 (en) 2012-07-26
BRPI0718813B1 (pt) 2020-12-08
EP2084172A1 (de) 2009-08-05
UY30709A1 (es) 2008-07-03
MX2009003958A (es) 2009-04-27
AU2007321496A1 (en) 2008-05-22
MA30883B1 (fr) 2009-11-02
TN2009000180A1 (en) 2010-10-18
NO344589B1 (no) 2020-02-03
US7956085B2 (en) 2011-06-07
CN101535326B (zh) 2012-10-31
DE102006053635B4 (de) 2011-06-30

Similar Documents

Publication Publication Date Title
CA2865332C (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
AU2008303975B2 (en) (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
AU2008303976B9 (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
RU2434003C2 (ru) Фениламинобензоксазолзамещенные карбоновые кислоты, способ их получения и их применение в качестве лекарственных средств
AU2007250211B2 (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
KR20090006847A (ko) 4,5-디페닐-피리미디닐 치환된 카복실산, 이의 제조 방법, 및 약물로서의 이의 용도
TW200837071A (en) Novel fluorine-substituted 1, 4-benzothiepine 1, 1-dioxide derivatives, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof
AU2009214278A1 (en) Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds, and the use thereof
AU2007315327A1 (en) Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties
DK2470552T3 (en) NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140926